Rheumatoid arthritis (RA) is an autoimmune disease characterized by bone and cartilage destruction, where immune cells such as macrophages, among others, play a crucial role in RA pathogenesis.
Researchers from Xuzhou Medical University and affiliated organizations have presented data from a study that assessed the protective effect of the natural flavonoid compound karanjin against sepsis-induced acute lung injury (ALI) in mice.
Researchers from Children’s Hospital Boston and affiliated organizations have reported the discovery and preclinical characterization of a novel TLR7/8 agonist adjuvant for vaccination, PVP-037.
Researchers in Japan have discovered that a phage-derived enzyme called endolysin, which targets highly resistant biofilm-forming bacteria, could help restore the gut microbiota to mitigate acute graft-vs.-host disease. Acute graft-vs.-host disease (aGVHD) is a common complication for patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT). Recent studies have highlighted the significant role of the microbiome in aGVHD, with dysbiosis contributing to its pathogenesis.
Immuneage Bio has announced its launch, with $2 million in funding and a focus on rejuvenating the immune system by targeting hematopoietic stem cells (HSCs) residing in the bone marrow.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYS-6016, the company’s mRNA respiratory syncytial virus (RSV) vaccine.
A new methodology based on the regulation of genetic enhancers has made it possible to develop a cellular map that reveals new types of helper T cells related to immunological disorders that could be explored for the development of new therapies. “I am very interested in the function of rare T cells, and I am trying to analyze their function by eliminating certain rare T cells with antibodies with ADCC [antibody-dependent cell-mediated cytotoxicity] activity or by disrupting genes that characterize rare T cells in animal models,” senior author Yasuhiro Murakawa told BioWorld.
At the Congress of the European Academy of Neurology, researchers from Dianthus Therapeutics Inc. presented preclinical data on DNTH-103, a monoclonal antibody engineered to selectively target the active form of complement C1s.
Pharma Foods International Co. Ltd. (PFI) has announced the achievement of a milestone under its licensing agreement with Mitsubishi Tanabe Pharma Corp. for a new investigational therapeutic antibody for autoimmune diseases.
MTX-101 (Mozart Therapeutics Inc.) is a bispecific CD8 Treg modulator that targets CD8 and the KIR2DL family, including KIR2DL1, KIR2DL2 and KIR2DL3, and is being developed for the treatment of CD4-driven autoimmunity and restoring immune balance.
RSS
